Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
调免I号
- Development stage
- Unknown
- Lead developer
- Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
- Administration
- Oral
01
Overview
调免I号 (Tiaomian No. 1) is a specialized Traditional Chinese Medicine (TCM) hospital-made preparation developed by the Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine. It is primarily indicated for the treatment of Systemic Lupus Erythematosus (SLE), particularly during the active phase characterized by Yin deficiency and internal heat in TCM theory. The formula consists of several botanical ingredients, including Rehmannia glutinosa and Scrophularia buergeriana, which work synergistically to modulate the immune system. Research indicates that 调免I号 functions by inhibiting the production of pro-inflammatory cytokines such as IL-6 and TNF-alpha, and by restoring the balance between Th17 and Treg cell populations, thereby reducing the autoimmune inflammatory response and protecting organ function.
- Other names
- Tiaomian I HaoTiaomian MixtureTiaomian Heji
02
Targets
IL-17A (Interleukin-17A)TNFA (Tumor necrosis factor alpha (soluble))IL-6 (Interleukin 6)
Beyond the preview
Go deeper on 调免I号.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 调免I号.